Sanofi India Ltd
Sanofi India Limited is amongst the leading multinational companies in the Indian Pharmaceutical Market. It offers a wide array of medicines for therapy areas such as Diabetes, Cardiology, Thrombosis, Central Nervous System and Anti-histamines.[1]
- Market Cap ₹ 14,175 Cr.
- Current Price ₹ 6,155
- High / Low ₹ 7,600 / 4,146
- Stock P/E 39.1
- Book Value ₹ 374
- Dividend Yield 1.91 %
- ROCE 49.2 %
- ROE 38.6 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- Stock is trading at 16.4 times its book value
- Debtor days have increased from 29.3 to 41.7 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Multinational
Part of BSE Allcap BSE 250 SmallCap Index BSE 400 MidSmallCap Index Nifty Microcap 250 Nifty Total Market
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Dec 2023 | Dec 2024 | |
---|---|---|
2,851 | 2,013 | |
2,044 | 1,522 | |
Operating Profit | 807 | 491 |
OPM % | 28% | 24% |
79 | 78 | |
Interest | 2 | 2 |
Depreciation | 40 | 37 |
Profit before tax | 846 | 531 |
Tax % | 29% | 22% |
603 | 413 | |
EPS in Rs | 262.13 | 179.70 |
Dividend Payout % | 64% | 65% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -29% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -39% |
Stock Price CAGR | |
---|---|
10 Years: | 11% |
5 Years: | 6% |
3 Years: | 7% |
1 Year: | 13% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | 39% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Dec 2023 | Dec 2024 | |
---|---|---|
Equity Capital | 23 | 23 |
Reserves | 992 | 838 |
19 | 19 | |
681 | 732 | |
Total Liabilities | 1,715 | 1,612 |
315 | 312 | |
CWIP | 16 | 18 |
Investments | 0 | 0 |
1,384 | 1,281 | |
Total Assets | 1,715 | 1,612 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Dec 2023 | Dec 2024 | |
---|---|---|
230 | 462 | |
38 | -19 | |
-878 | -392 | |
Net Cash Flow | -610 | 50 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Dec 2023 | Dec 2024 | |
---|---|---|
Debtor Days | 17 | 42 |
Inventory Days | 202 | 186 |
Days Payable | 89 | 151 |
Cash Conversion Cycle | 130 | 77 |
Working Capital Days | 25 | 21 |
ROCE % | 49% |
Documents
Announcements
- Closure of Trading Window 4 Apr
-
Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015
2 Apr - Disclosure of High Court order for rebate claim.
-
Announcement under Regulation 30 (LODR)-Dividend Updates
18 Mar - Approval of AGM, dividend, and director re-appointment.
-
Announcement under Regulation 30 (LODR)-Change in Directorate
18 Mar - Board approved AGM date, dividend, and director re-appointment.
- Record Date For Final Dividend For The Financial Year Ended 31St December 2024 18 Mar
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2013
from nse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Concalls
-
May 2024Transcript PPT
-
Feb 2024TranscriptPPT
-
Feb 2024Transcript PPT
-
Nov 2023TranscriptPPT
-
Nov 2023Transcript PPT
-
May 2023Transcript PPT
-
May 2023TranscriptPPT
-
Feb 2023TranscriptPPT
-
Feb 2023TranscriptPPT
-
Mar 2021TranscriptNotesPPT
Parent Company[1]
Sanofi Global and its 100% subsidiary - Hoechst GmbH, are the shareholders of Sanofi India and together hold 60.40%. Company's follows parent company's financial year hence, Financial year is same as Calender Year.